The effect of dapagliflozin in Chinese elderly patients with heart failure
Jia YOU
Jing-Zhi ZHENG
Jia LIU
Xiang GU
Ye ZHU
Abstract：Clinical guidelines typically classify heart failure (HF) into three categories based on left ventricular ejection fraction (LVEF): reduced (HFrEF), mildly reduced (HFmrEF), and preserved (HFpEF). [1] Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been demonstrated to lower cardiovascular mortality and HF events. The EMPEROR trials indicated similar efficacy and safety for SGLT2 inhibitors compared to placebo in outpatients with HFrEF as well as HFmrEF and HFpEF. [2] A meta-analysis showed that dapagliflozin decreased the risk of cardiovascular death and hospital admissions for HF across the LVEF spectrum. [3] However, a comprehensive evaluation of dapagliflozin's efficacy and safety across the baseline LVEF spectrum in Chinese patients with HF is still lacking. [4] Therefore, this study aims to investigate the efficacy and safety of dapagliflozin across the full range of LVEF in Chinese patients.
Machine-generated Keywords：
Publication Date：2025-11-30
Online Publishing Date：2026-01-09(First online date of this platform, not the publication date of the document)
Pages：5( 948-952 )